Clinical trial
Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage…
NCT00431015 · Infinity Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00431015 |
|---|---|
| Title | Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC) |
| Official title | A Phase I/II Study to Investigate the Safety, Tolerability and Potential Activity of IPI-504 in Relapsed and / or Refractory Stage IIIb (With Malignant Pleural or Pericardial Effusion), or Stage IV NSCLC Patients |
| Lead sponsor | Infinity Pharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | IPI-504 |
| Enrollment | 88 |
| Start date | Jan 1, 2007 |
| Primary completion | Aug 1, 2011 |
| Completion | Dec 1, 2011 |
| First posted | Feb 2, 2007 |
| Last update posted | Dec 10, 2012 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: